Indication

In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
SMC2385
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
07 February 2022
SMC meeting date:
11 January 2022
Patient group submission deadline:
06 September 2021